参考文献:
[1]. PhaseI, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283),an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.J Clin Oncol 2020 Jul 1;38(19):2140-2150.
[2]. KRAS(G12C)Inhibition with Sotorasib in Advanced Solid Tumors.NEngl J Med. 2020 Sep 24;383(13):1207-1217.
[3]. Ivosidenibin IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): amulticentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020 Jun;21(6):796-807
[4]. APhase II Trial of Tipifarnib for Patients with Previously Treated, MetastaticUrothelial Carcinoma Harboring HRAS Mutations.ClinCancer Res2020 Oct 1;26(19):5113-5119.
[5]. Intermittentschedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients withRAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label,phase 1 dose-escalation and basket dose-expansion study.Lancet Oncol 2020 Nov;21(11):1478-1488
[6]. PhaseII Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFRPathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.J Clin Oncol2020 Jul 20;38(21):2407-2417
[7]. PhaseI Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or inCombination With Carboplatin in Patients With Advanced Solid Tumors.J Clin Oncol2020 Sep 20;38(27):3195-3204
[8]. AntitumorActivity and Safety of Trastuzumab Deruxtecan in Patients WithHER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.J Clin Oncol2020 Jun 10;38(17):1887-1896.
[9]. PhaseI Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patientswith PIK3CA-Mutant Cancers.ClinCancer Re2020 Nov 4;clincanres.2657.2020
[10]. https://www.onclive.com/view/mobocertinib-continues-to-show-clinical-activity-in-egfr-exon-20-mutant-nsclc